vimarsana.com

Page 49 - நிறுவனம் ஆஃப் உயிரியல் ப்ராடக்ட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coronavirus: China s Sinopharm seeks general use green light for second vaccine

Vaccines on the menu | Special Report

So far, ten anti-COVID-19 virus vaccines have been authorised for use in various parts of the world The Corona virus that has caused the current pandemic is called SARS-CoV-2, or Severe Acute Respiratory Syndrome Corona Virus-2. The disease itself is called COVID-19, or Corona Virus Disease, 2019. So far, ten anti-COVID-19 virus vaccines have been authorised for use in various parts of the world. Eighty one vaccines are undergoing trials with twenty at advanced stages. The first one to arrive in Pakistan is a Chinese vaccine made by the state owned Chinese company, Sinopharm. It was developed by the Beijing Institute of Biological Products. It is a whole virus, killed vaccine and has been given an ‘emergency use authorisation’ by the Drug Regulatory Authority of Pakistan (DRAP). The results of the large scale clinical trials, called Phase III trials have not been published yet in peer reviewed medical journals. The trials have taken place in various countries, including UAE an

SAMAA - COVID-19 Pakistan: Who should and shouldn t get the Sinopharm vaccine

COVID-19 Pakistan: Who should and shouldn’t get the Sinopharm vaccine It is not recommended for the elderly and pregnant women SAMAA | Health - Posted: Feb 6, 2021 | Last Updated: 2 months ago SAMAA | Health Posted: Feb 6, 2021 | Last Updated: 2 months ago A health worker receives a dose of the Sinopharm vaccine at Dow University of Health Sciences, Karachi. Photo: Online Listen to the story The National Ministry of Health Services and Regulations has released guidelines for the administration of the Sinopharm COVID-19 vaccine being used in Pakistan. The guidelines are based on the current results from clinical trials and might change as new information becomes available.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.